Current Report Filing (8-k)
September 29 2016 - 7:37AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): September 26, 2016
Cytokinetics, Incorporated
(Exact name of
registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50633
|
|
94-3291317
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
280 East Grand Avenue,
South San Francisco,
California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650) 624-3000
Not Applicable
Former name or
former address, if changed since last report
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
On September 26, 2016, Cytokinetics, Incorporated (
Cytokinetics
) received notice that the Federal Trade
Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the 2016 amendment to the License and Collaboration Agreement initially executed between
Cytokinetics and Astellas Pharma Inc., in 2013 and amended in 2014. In July 2016, the companies expanded the collaboration related to the research, development and commercialization of skeletal muscle activators. With the termination of the
applicable waiting period under the HSR Act, the 2016 amendment is deemed effective as of Sept. 26, 2016 and the upfront payment of $65 million from Astellas to Cytokinetics is due and payable within 30 days.
A copy of the press release, titled Cytokinetics Announces Early Termination of Hart-Scott-Rodino Waiting Period for
Expanded Collaboration with Astellas is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release, dated September 29, 2016, titled Cytokinetics Announces Early Termination of Hart-Scott-Rodino Waiting
Period for Expanded Collaboration with Astellas.
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed
on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CYTOKINETICS, INCORPORATED
|
|
|
|
|
Dated: September 29, 2016
|
|
|
|
By:
|
|
/s/ Sharon A. Barbari
|
|
|
|
|
|
|
Sharon A. Barbari
|
|
|
|
|
|
|
Executive Vice President and Chief Financial Officer
|
Exhibit List
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Press Release, dated September 29, 2016, titled Cytokinetics Announces Early Termination of Hart-Scott-Rodino Waiting
Period for Expanded Collaboration with Astellas.
|
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024